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e effect of 16𝛼𝛼-bromoepiandrosterone (EpiBr), a dehydroepiandrosterone (DHEA) analogue, was tested on the cysticerci of
Taenia solium, both in vitro and in vivo. In vitro treatment of T. solium cultures with EpiBr reduced scolex evagination, growth,
motility, and viability in dose- and time-dependent fashions. Administration of EpiBr prior to infection with T. solium cysticerci in
hamsters reduced the number and size of developed taenias in the intestine, compared with controls. ese effects were associated
to an increase in splenocyte proliferation in infected hamsters. ese results leave open the possibility of assessing the potential of
this hormonal analogue as a possible antiparasite drug, particularly in cysticercosis and taeniosis.
1. Introduction
Cysticercosis, caused by the metacestode stage of Taenia
solium, is a serious health and veterinary problem in many
developing countries [1–3]. In humans, T. solium cysticerci
cause neurocysticercosis, which affects ∼50 million people
worldwide, and it has been considered as an emergent disease
in the United States [4]. T. solium also infects pigs, its
intermediate host, leading to major economic losses [5, 6].
When humans ingest undercooked contaminated pork
meat, the adult worm develops in the small intestine. Aer
two months of asymptomatic infection, this tapeworm starts
producing thousands of eggs, that, once released with the
stools, can contaminate the environment, infecting pigs
(rapidly differentiating into cysticerci mainly in the muscle)
and humans (where most severe symptoms are observed due
to the presence of cysticerci in the brain) [1, 7].
us, maintenance of the parasite’s life cycle depends
on the adult tapeworm development [8]. In fact, even in
communities which do not rear or consume pigs, human
neurocysticercosis can be found, because of the presence
of a tapeworm carrier [9, 10]. Furthermore, tapeworm
development in turn depends on scolex evagination, the
initial step through which a single cysticercus becomes an
adult parasite with capability of producing infective eggs
[11].
Dehydroepiandrosterone (DHEA) is a steroid hormone
produced from cholesterol by the adrenal glands, the gonads,
adipose tissue, and the brain. It is the most abundant
hormone in the human body. In humans and in mammals
generally (except for rodents), DHEA is the dominant steroid
hormone and precursor of sex steroids and has proved to
be an important molecule in the immune responses that
could drive resistance against a variety of infections [12,
13]. ese infections include intracellular parasites such as
Cryptosporidium parvum [14] and Plasmodium falciparum
[15] as well as extracellular parasites such as E. histolyt-
ica [16], Schistosoma mansoni [17], and Taenia crassiceps
[18], among others. 16-bromoepiandrosterone (EpiBr), a
DHEA analogue without signi�cant androgenic activity and
also known as HE2000, has shown activity in a number
of infectious disease settings, including tuberculosis [19],
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feline immunode�ciency virus viremia [20], malaria [21],
cysticercosis by T. crassiceps, and amoebiasis by E. histolytica
[16]. As it can be seen, direct effects of sex steroids upon
helminth parasites (cestodes, nematodes, and trematodes)
and protozoan parasites are not unusual. In fact, previous
results suggest that these pathogens not only are directly
affected by adrenal hormones, but they have also developed
several strategies to exploit the host’s endocrine microenvi-
ronment [22, 23], which include degradation of host proteins
as an alternative source of amino acids [24], development of
parasitic-sex steroid receptors [25, 26], and cross-activation
of signal transduction pathways [27, 28].
Taking into consideration this information, the aim of
the present study was to explore whether EpiBr has direct
in vitro and in vivo modulating effects on T. solium. Our
results suggest that EpiBr treatment may be used as a
new therapeutic approach against natural cysticercosis and
taeniosis.
2. Materials andMethods
2.1. Ethics Statement. Animal care and experimentation
practices at the Instituto de Investigaciones Biomédicas are
frequently evaluated by the Institute’s Animal Care and Use
Committee, according to the official Mexican regulations
(NOM-062-ZOO-1999). Mexican regulations are in strict
accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health (NIH and e Weatherall Report) of the
USA, to ensure compliance with established international
regulations and guidelines. e protocol was approved by
the Committee on the Ethics of Animal Experiments of
the Instituto de Investigaciones Biomédicas (Permit number
2009-16). Pigs sacri�ce to obtain parasites was performed
under sodium pentobarbital anesthesia, and all efforts were
made to minimize suffering. All animals were maintained in
a common room under controlled temperature and a 14 h
dark/10 h light cycle in the animal facility of the Biological
Sciences Building at the Institute of Biomedical Research
(IIB).
2.2. Obtention of Parasites. T. solium cysticerci were dis-
sected from the muscle of infected pigs, which were eutha-
nized at the Veterinary School of the Universidad Nacional
Autónoma de México. e method was previously evaluated
by the University Animal Care and Use Committee to ensure
compliance with international regulations and guidelines.
e �brous capsule that surrounds each parasite was carefully
separated with the use of a dissection microscope. Once
dissected, cysticerci were placed in tubes containing ster-
ile PBS (1X) supplemented with 100U/mL of antibiotics
fungizone (Gibco, Grand Island, NY) [29]. Samples were
centrifuged for 10min, at 800 g at 4∘C, and the supernatant
was discarded. Pellets containing cysticerci were incubated
in Dulbecco’s Modi�ed Eagle Medium (DMEM) without
fetal serum supplementation (Gibco, BRL, Rockville, MD).
ey were then washed by centrifugation 3 times for 10min
at 800 g with DMEM. A�er the �nal wash, viable parasites
(complete and translucent cystic structures) were counted
using a binocular microscope.
2.3. In Vitro EpiBr Assays. Culture grade 16𝛼𝛼-bromoepian-
drosterone (EpiBr) was obtained from Hollis-Eden Pharma-
ceuticals. EpiBr was dissolved in corn oil to the desired stock
concentration and sterilized by passage through a 0.2𝜇𝜇m
millipore �lter. �or in vitro tests against T. solium cysticerci,
hormone analogue was dissolved in corn oil and AIM-V
(free of calf serum and other hormones) culture medium
to the desired stock concentration and sterilized by passage
through a 0.2 𝜇𝜇m millipore �lter. e experimental design
was as follows: using a 24-well culture plate, six wells were
used for untreated controls, six wells were supplemented with
the vehicle in which EpiBr was diluted, and six wells were
treated with different concentrations of EpiBr. e analogue
concentrations usedwere based on theDHEA concentrations
of serum levels found in humans and other species and
were chosen to approximate analogue levels in vivo. e
analogue was administered every other day, based on the
time that DHEA (the natural hormone) remains circulating
before being metabolised and �ltered in the kidney. is
assures that there is no toxic effect of the analogue, and
the circulating levels are proximate to what we want. Our
concentrations were calculated to resemble those observed
in vitro and going from lower to higher levels. However, we
converted the doses to concentrations, in order to be in line
withmost of the studies that use hormones in vitro and report
those doses in terms of concentration as micromolar. So,
based on these facts, we choose analogue doses to be used
in both experimental systems. Concentrations of EpiBr were
randomised across the plates. Control cysticerci were treated
with the solvent in which EpiBr was diluted, so that a constant
volume of solvent (2mL) was added to each well. Scolex
evagination and worm length were daily determined in all
cultured cysticerci using an inverted microscope (Olympus,
MO21, Tokyo) at 10x and 20x magni�cation. Worm length
was considered as the millimetric addition of scolex, neck,
and strobila. Immediately, the new cultures (2mL in glass
tubes) were added with 50 𝜇𝜇L of corn oil diluted in medium
(control) or 50 𝜇𝜇L of several concentrations of EpiBr ranging
from 0.1 to 50 𝜇𝜇g/mL. Samples of 100 𝜇𝜇L were collected from
the same tube with a particular dose at 24, 48, and 72 h by
ice chilling for 5min and centrifugation at 150 g for 5min at
4∘C.
2.4. In Vivo Infections with T. solium. T. solium cysticerci
were selected according to the macroscopic criteria reported
by León-Cabrera and coworkers [30]. Brie�y, parasites were
dissected from muscle of naturally infected pigs, which were
euthanized at the Veterinary School of the Universidad
Nacional Autónoma deMéxico, under consent of the Univer-
sity Animal Care and Use Committee to ensure compliance
with international regulations and guidelines. e �brous
capsule surrounding each parasite was carefully separated
under a dissection microscope. Once separated, cysticerci
were placed in tubes containing sterile PBS (1X) supple-
mented with 100U/mL of antibiotics fungizone (Gibco,
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Grand Island, NY). Samples were centrifuged at 800 g at
4∘C for 10min, and the supernatant was discarded. Pellets
containing cysticerci were placed in Dulbecco’s Modi�ed
EagleMedium (DMEM,Gibco, BRL, Rockville,MD)without
fetal serum supplementation. en, they were washed and
centrifuged 3 times at 800 g at 4∘C for 10min. Aer the �nal
wash, complete and translucent reddish cysticerci were incu-
bated on 6-well culture plates containing DMEM medium
with 25% pig fresh bile supplementation for infectivity test.
When the evagination rate was higher than 90%, then
parasites were used for subsequent oral infections.
2.5. EpiBr Administration. Twenty male golden hamsters
(Mesocricetus auratus) of 140–160 gr, aging between 8 and
10 weeks, were subcutaneously administered with 2mg/Kg
body weight of EpiBr. Ten were infected with T. solium
as previously described. Each single dose of EpiBr was
diluted in 0.4mL of saline solution (0.9% NaCl, Baker).
Control infected animals (𝑛𝑛 𝑛 𝑛𝑛 for T. solium infections)
received 0.4mL of saline solution as vehicle. A stress-related
additional control group (𝑛𝑛 𝑛 𝑛𝑛 for T. solium infections)
was included in our experiments, which consisted in ten
sham injection animals. Hormone analogue and vehicle
administration was carried out each other day during four
weeks, in order to maintain the same hormonal serum
concentration for the entirely time of the experiment. Our
results were obtained from two independent experiments
performed in similar conditions. Animals were fed with
Purine Diet 5015 (Purine, St. Louis, MO) and water ad
libitum during all the experiment. During animal necropsy,
the entire small intestine and liver were dissected and placed
on a Petri dish containing sterile PBS (1X) (Sigma-Aldrich,
USA).Using a stereoscopicmicroscope, the lumenof all small
intestines was carefully exposed bymaking a longitudinal cut
using sterile dissection scissors. en, duodenum-anchored
parasites were counted and measured with a calibrator.
Blood samples were individually collected from all ani-
mal groups for posterior serum analysis. Ileum attachment
zones where T. solium scolices were located were placed
in 4% paraformaldehyde (J. T. Baker, México), or Trizol
reagent (Invitrogen, Carlsbad, CA) for posterior analysis.
Immediately aer necropsy, spleen weight was individually
recorded. Spleen and liver samples from all animal groups
were individually obtained and placed in RPMI (Gibco, BRL,
Rockville, MD) supplemented with 10% fetal calf serum
(Gibco, BRL, Rockville, MD), or 4% paraformaldehyde (J. T.
Baker, México), or Trizol reagent (Invitrogen, Carlsbad, CA)
for posterior analysis.
2.6. Cell Culture and Lymphoid Proliferation. Total leuko-
cytes and red blood cells were extracted from spleen and
mesenteric lymph nodes of all animal groups. Aer single
washing with ACK Lysing Buffer (Invitrogen, USA), total
leukocytes were recovered and cultured in 96-well sterile
plates (1 × 104 cells/well) containing serum-free RPMI
medium (Gibco-BRL), at 37∘C in humidi�ed 5% CO2 atmo-
sphere for 72 h. Aer this time, cultured leukocytes from
spleen and mesenteric lymph nodes of all animals were
exposed to 15 𝜇𝜇g/well of freshly extracted T. solium total
antigen during 48 h. Twenty-four hours before the end of the
experiment, 20 𝜇𝜇L ofAlamarBlue reagent (Biosource Interna-
tional) were added to each culture well. en, culture plates
were frozen at −30∘C under darkness and the absorbance
was quanti�ed at 570 and 600 nm, using a microplate reader.
e 570–600 nm lecture coefficient was employed to assess
proliferation index.
2.7. Experimental Design and Statistical Analysis. We used
a two factorial experiment. Independent variables were (1)
treatment (two levels: EpiBr or vehicle); and (2) infection
(two levels: Yes, No).e dependent variable was the number
and size of parasites. Two in vivo experiments were per-
formed, and data were analysed using one-way analysis of
variance (ANOVA). When performed, post hoc individual
contrasts of group means to test for signi�cant differences
were carried out using t-tests. Hormone dose-response time
curves were estimated in three independent experiments
performed with freshly isolated T. solium cysticerci. EpiBr
was tested at �ve different doses; each dose was run in
triplicate. Differences between groups were estimated by the
ANOVA test. Post hoc analysis used was the t-test to examine
for signi�cant differences. Differences were considered sig-
ni�cant when 𝑃𝑃 𝑃 𝑛𝑃𝑛𝑛. e soware Prism 2.01 (GraphPad
Soware Inc.) was used to calculate probability values.
3. Results
3.1. In Vitro Effect on T. solium Cysticerci. When T. solium
cysticerci were in vitro exposed to EpiBr, a decrease in
the scolex evagination was observed in all treated para-
sites compared to control groups (Figure 1(a)). However,
this evagination-inhibiting effect mediated by EpiBr was
independent of the tested concentrations (Figure 1(a)).
Concomitantly, the evagination-inhibiting effect of EpiBr
(0.25 𝜇𝜇M) was maintained through all 10 days of in vitro
culture, reaching its highest response on the third day of
culture, in relation to control and vehicle parasites (Figure
1(b)). It is important to mention that viability of evaginated
cysticerci was veri�ed daily by means of wormmotility in the
culture plate, which was constant through all days of in vitro
culture. Injured parasites were recognized by a progressive
internal disorganization: development of opaque areas in the
tegument and loss of translucence of the vesicle.
EpiBr also affected in vitroworm growth. From the lowest
concentration (0.1 𝜇𝜇M), EpiBr inhibited worm length on day
10 (measured as the addition of scolex, neck, and strobila
of the developing parasite) with respect to the control group
and reached a plateau (Figure 2(a)). In addition, the T. solium
worm gradually decreased up in response to 0.5 𝜇𝜇M of EpiBr
(Figure 2(b)). Differentiated worms in absence of hormones
or vehicle stimulus had a spontaneous development, reaching
their maximum length (8.5mm) at 3 day in culture. Once
again, in the presence of EpiBr, no worm differentiation was
observed with 2.0 𝜇𝜇M along all the time of in vitro culture.
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F 1: EpiBr decreased scolex evagination of Taenia solium in a
concentration-dependent pattern (a) maintained along the time (b).
In concentration-response curves (panel (a)), cysticerci treated with
vehicle are referred to as concentration zero. Data are represented as
mean +/− SD. ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
3.2. In Vivo Effect on T. solium Infection. Aer 15 days aer
infection, EpiBr treatment signi�cantly reduced the number
of intestinally anchored T. solium tapeworms by 80–87%
(Figure 3(a)). Vehicle-treated and control-infected hamsters
showed between three and four viable parasites (Figure 3(a)).
It is important to remark that all found tapeworms were
strongly attached to the duodenum zone. As expected, tape-
worms from vehicle-treated and control-infected hamsters
grew up more than 8𝑃8 ± 1𝑃6mm (Figure 3(b)). In contrast,
parasite from EpiBr-treated hamsters did not develop more
than 1𝑃7 ± 𝑃𝑃3mm in length (Figure 3(b)), showing besides
poorly differentiated scolices. us, steady concentrations of
EpiBr exerted a protective role against the T. solium intestinal
infection, diminishing both the number of attached parasites
and their development.
To assess the possible mechanism involved in EpiBr
protective actions during infection, spleens from all ani-
mal groups were weighed and splenic leukocytes assayed
for antigen-speci�c proliferation (Figure 4). Signi�cant
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F 2: EpiBr decreases worm growth in a concentration-
dependent pattern (a), reaching its maximum effect at 4 days of
in vitro during the whole culture time (b). EpiBr-treated parasites
were motile and undamaged on the culture plate. Worm length was
considered as the addition (mm) of scolex, neck, and strobila. In the
concentration-response curves (panel (a)), cysticerci treated with
vehicle are referred to as concentration zero. Data are represented
as mean +/− SD. ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃.
differences were observed among the spleen weight from
EpiBr-treated hamsters, compared with vehicle-treated ani-
mals and control-infected hamsters (Figure 4(a)), where
hamsters exposed to EpiBr increase spleen weight with
respect to their infected control littermates. Furthermore, in
vivo EpiBr treatment clearly increased proliferation in vitro
of T. solium antigen-speci�c leukocytes by 3.5-fold compared
to both infected control groups (Figure 4(b)). is result
suggests that EpiBr should protect hamsters from T. solium
infection through promotion of a local mucosal antiparasite
immune response.
4. Discussion
It has been reported that exogenous DHEA administration
upregulates the immune system, speci�cally the cellular
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F 3: EpiBr decreases both parasite load and tapeworm length in T. solium cysticerci orally infected hamsters. (a) Administration of
BrEpi signi�cantly diminished the number of intestinally attached adult tapeworms by ����7%, with respect to both control and vehicle
infected groups. (b) Parasites exposed to constant concentrations of BrEpi showed total length reduction of fourfold. ese parasites seemed
as undifferentiated scolices with no develop of neck and strobila, compared to those tapeworms from control and vehicle groups with well-
differentiated structures. Tapeworm length was determined as the longitudinal sum of scolex, neck, and strobila. Nonmanipulated infected
hamsters were denominated as control, meanwhile comparative lines represent signi�cant differences when 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃. Results are presented
as mean +/− standard deviation.
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F 4: EpiBr administration increases proliferation rate of parasite speci�c leukocytes from spleen. (a) EpiBr-treated animals showed a
tendency to increase spleen weight, with respect to control- and vehicle-treated animals. (b) Spleen leukocytes from EpiBr-treated, vehicle,
and control infected hamsters were in vitro cultured in presence of T. solium total antigen. As a consequence of the in vivo exposition to EpiBr,
the leukocyte proliferation index in presence of parasitic antigen was augmented by 3.5- and 2.7-fold, compared to immune cells from both
control- and vehicle-treated hamsters, respectively. Results are presented as mean +/− standard deviation. ∗∗𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 versus the other groups.
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immune response, by increasing the natural killer cell num-
ber and function [13]. Our previous �ndings do not support
this notion, since IL-2 mRNA levels do not change in
response to DHEA treatment. e lack of effect of DHEA on
cytokinemRNAbut its dramatic effect in vivo onparasite load
and parasite reproduction and in vitro on survival supports
the hypothesis that DHEA analogue exerts its protective
properties via direct effects on the parasite. To the best of our
knowledge, this effect is consistent with the known effects
of DHEA on the survival of other parasites, both metazoan
[17, 31] and protozoan [16].
For instance, it has been suggested that in human schisto-
somiasis, DHEA is the cause of the puberty-associated drop
in susceptibility [32].is idea has been reinforced by experi-
ments in which treatment of mice with the bloodstream form
of DHEA, DHEA-S (DHEA-sulfate), protected them from
infection with S. mansoni [17] and mice against T. crassiceps
infection [18].
Other �ndings in mice of a decrease in DHEA levels
as infection progresses agree with previous results in a S.
mansoni-baboon model, in which baboons with primary
infections showed decreasing levels of DHEA as the infec-
tion progressed, compared with uninfected and reexposed
baboons [31].
e protective effect of DHEA has also been demon-
strated in parasitic infections like T. cruzi, where increase the
levels of lytic antibodies and to reduce T. cruzi parasitemia
in rats [33] or in the protozoan parasite C. parvum, where
signi�cantly reduced both the shedding of fecal oocysts and
parasite colonisation of the ileum [34, 35]. On the other
hand, 16-bromoepiandrosterone (EpiBr), a DHEA analogue
without signi�cant androgenic activity and also known as
HE2000, has activity in a number of infectious disease set-
tings [16, 18–20]. Here, we explored whether EpiBr has direct
in vitro and in vivo modulating effects on T. solium and the
immunomodulating effects on E. histolytica reproduction,
growth, viability, and infectivity.
e in vitroDHEA treatment ofE. histolytica trophozoites
also reduced the growth and viability of this parasite. e
effects of DHEAwere associated with the inhibition of G6PD
activity [16]. Also, DHEA is known to exert antimalarial
protection, via the enhanced opsonisation and phagocytosis
of rings, the early forms of this parasite [36, 37]. Our results
con�rm and extend the notion that DHEA is a strong
parasiticidal agent, since in vitro EpiBr treatment of T. solium
remarkably reduced the reproduction rate and viability of
cysticerci. Also, in our present experiments, the effects of
EpiBr signi�cantly reduced the parasite burden in males.
Finally, our results support and extend the notion that EpiBr
is a potentially useful treatment against a large variety of
parasitic diseases. e fact that EpiBr interferes with the
development of T. solium cysticerci may be applied to the
development of future therapeutic protocols against this
parasite that affects pigs and humans.
DHEA is a hormone able to inhibit the in vitro growth of
numerous parasites, includingT. crassiceps, a murine cestode,
and E. histolytica, the causal agent of amoebiasis in human
[16, 18]. Such results, in addition to the bene�ts discovered
for this hormone on neuroprotection, anxiety, depression,
schizophrenia, dementia, some neoplasias such as breast
cancer, diabetes, and numerous in�ammatory disorders [38–
40], have raised discussion about the possibility of using the
DHEA analogue, EpiBr, for therapeutic purposes, includ-
ing the control of parasitic diseases. us, analogs lacking
androgenic activity but maintaining the other biological
activities of the natural steroid have been designed. In this
study, we provide evidence demonstrating the ability of the
analog EpiBr for inhibiting the establishment and growth
of T. solium. In vitro, the effect of the analogue on the
parasite was observed in several parameters of cell and
organic functionality, affecting the establishment and growth
and survival in general. ese effects were similar to those
previously reported by our group regarding the in vitro
effect of DHEA on both Taenia crassiceps and Entamoeba
histolytica [16–18]. Our results are in agreement with similar
inhibitory effect shown for the analog on the proliferation of
P. falciparum and P. berghei parasites in vitro [21].
e in vitro inhibitory effects of EpiBr on T. solium were
also extended to the in vivo infections. us, treatment with
the analog decreased the T. solium cysticerci evagination and
growth up to 80–87% in hamsters.
Since EpiBr enhanced splenocyte proliferation, we sug-
gest that its in vivo protective activity was likely due, at least
in part, to a possible immunomodulatory effect on the host
by EpiBr. e latter theory could be in fact involved as EpiBr
has anti-in�ammatory properties and it is also able to induce
cellular immunity that may aid the control of infections
[19, 41, 42]. Our results in vivo are also in agreement with
previous studies supporting a potential pharmacological
use of EpiBr to treat infections such as tuberculosis, AIDS,
and malaria [19, 21, 41, 42]. us, administration of
intramuscular HE2000 in patients with P. falciparummalaria
resulted in a 50% reduction of parasitemia with notably
improve in symptomatology and mild adverse events [43].
5. Conclusion
We have demonstrated that EpiBr is a promising new com-
pound that can be used in cysticercosis, taeniosis. e results
of this study leave open the possibility of assessing the poten-
tial of this analog of DHEA as an antiparasitic drug, and in
particular against human/pig cysticercosis, taeniosis, major
health public problems by parasites in developing countries.
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